These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 24939611)

  • 1. Oncolytic polio virotherapy of cancer.
    Brown MC; Dobrikova EY; Dobrikov MI; Walton RW; Gemberling SL; Nair SK; Desjardins A; Sampson JH; Friedman HS; Friedman AH; Tyler DS; Bigner DD; Gromeier M
    Cancer; 2014 Nov; 120(21):3277-86. PubMed ID: 24939611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineered Oncolytic Poliovirus PVSRIPO Subverts MDA5-Dependent Innate Immune Responses in Cancer Cells.
    Walton RW; Brown MC; Sacco MT; Gromeier M
    J Virol; 2018 Oct; 92(19):. PubMed ID: 29997212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant Poliovirus for Cancer Immunotherapy.
    Gromeier M; Nair SK
    Annu Rev Med; 2018 Jan; 69():289-299. PubMed ID: 29414253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models.
    Holl EK; Brown MC; Boczkowski D; McNamara MA; George DJ; Bigner DD; Gromeier M; Nair SK
    Oncotarget; 2016 Nov; 7(48):79828-79841. PubMed ID: 27806313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic immunotherapy through tumor-specific translation and cytotoxicity of poliovirus.
    Brown MC; Gromeier M
    Discov Med; 2015 May; 19(106):359-65. PubMed ID: 26105699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Designer nanocarriers for navigating the systemic delivery of oncolytic viruses.
    Howard F; Muthana M
    Nanomedicine (Lond); 2020 Jan; 15(1):93-110. PubMed ID: 31868115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytotoxic and immunogenic mechanisms of recombinant oncolytic poliovirus.
    Brown MC; Gromeier M
    Curr Opin Virol; 2015 Aug; 13():81-5. PubMed ID: 26083317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy.
    Shin DH; Nguyen T; Ozpolat B; Lang F; Alonso M; Gomez-Manzano C; Fueyo J
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomodulation in Oncolytic Measles Virotherapy.
    Dietz L; Engeland CE
    Methods Mol Biol; 2020; 2058():111-126. PubMed ID: 31486034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. To Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic Viruses.
    Cassady KA; Haworth KB; Jackson J; Markert JM; Cripe TP
    Viruses; 2016 Feb; 8(2):. PubMed ID: 26861381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrating oncolytic viruses in combination cancer immunotherapy.
    Bommareddy PK; Shettigar M; Kaufman HL
    Nat Rev Immunol; 2018 Aug; 18(8):498-513. PubMed ID: 29743717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Circuits of Immune Sensing and Response to Oncolytic Virotherapy.
    Bhatt DK; Daemen T
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virotherapy in Germany-Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies.
    Nettelbeck DM; Leber MF; Altomonte J; Angelova A; Beil J; Berchtold S; Delic M; Eberle J; Ehrhardt A; Engeland CE; Fechner H; Geletneky K; Goepfert K; Holm PS; Kochanek S; Kreppel F; Krutzke L; Kühnel F; Lang KS; Marchini A; Moehler M; Mühlebach MD; Naumann U; Nawroth R; Nüesch J; Rommelaere J; Lauer UM; Ungerechts G
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fighting Cancer with Viruses: Oncolytic Virus Therapy in China.
    Wei D; Xu J; Liu XY; Chen ZN; Bian H
    Hum Gene Ther; 2018 Feb; 29(2):151-159. PubMed ID: 29284308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potentiating oncolytic viral therapy through an understanding of the initial immune responses to oncolytic viral infection.
    Alvarez-Breckenridge CA; Choi BD; Suryadevara CM; Chiocca EA
    Curr Opin Virol; 2015 Aug; 13():25-32. PubMed ID: 25846988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic Immunotherapy for Treatment of Cancer.
    Tsun A; Miao XN; Wang CM; Yu DC
    Adv Exp Med Biol; 2016; 909():241-83. PubMed ID: 27240460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining oncolytic virotherapy and tumour vaccination.
    Bridle BW; Hanson S; Lichty BD
    Cytokine Growth Factor Rev; 2010; 21(2-3):143-8. PubMed ID: 20226716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic Immunotherapy.
    Hennessy ML; Bommareddy PK; Boland G; Kaufman HL
    Surg Oncol Clin N Am; 2019 Jul; 28(3):419-430. PubMed ID: 31079797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Introduction to Oncolytic Virotherapy.
    Engeland CE; Bell JC
    Methods Mol Biol; 2020; 2058():1-6. PubMed ID: 31486028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virus specific tolerance enhanced efficacy of cancer immuno-virotherapy.
    Sobhanimonfared F; Bamdad T; Sadigh ZA; Choobin H
    Microb Pathog; 2020 Mar; 140():103957. PubMed ID: 31891795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.